Literature DB >> 28844013

Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.

Jermaine D Jones1, Jeanne M Manubay2, Shanthi Mogali2, Verena E Metz2, Gabriela Madera2, Suky Martinez3, Mudassir Mumtaz3, Sandra D Comer2.   

Abstract

BACKGROUND: This study sought to determine the relative importance of a range of Bup/Nx doses compared to Bup alone in producing subjective and reinforcing effects.
METHODS: Heroin-using volunteers (n=13) were transitioned onto daily oral hydromorphone (40mg). Laboratory sessions assessed the reinforcing and subjective effects of intravenous (IV) doses of Bup (1.51, 2.16, 6.15, and 8.64mg) and Bup/Nx (1.51/0.44, 2.16/0.61, 6.15/1.71, and 8.64/2.44mg). Placebo (Pbo), heroin (25mg) and Nx (0.3mg) were tested as neutral, positive, and negative controls, respectively.
RESULTS: IV Bup alone was self-administered substantially less than IV heroin, though the two largest doses of Bup produced positive subjective effects, drug "Liking" (0-100mm), which were comparable to heroin (mean difference: Heroin vs Bup 6.15mg: -3.4mm, Heroin vs Bup 8.64mg: -11.3mm). All indicators of abuse potential seen with IV Bup alone were substantially decreased with the addition of Nx. All Bup/Nx combinations produced ratings of aversive effects, "Bad", which were comparable to, or greater than IV, Nx. On three of the four measures of aversive effects, the largest difference is seen with the 8.64 vs 8.64/2.44 condition.
CONCLUSIONS: This study further demonstrates the ability of the Bup/Nx combination to deter IV use. Although none of the Bup/Nx combinations showed indications of abuse potential, formulations with larger absolute Nx, may be less abusable as they precipitate a greater degree of withdrawal.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abuse liability; Buprenorphine; Intravenous; Opioid; Self-administration

Mesh:

Substances:

Year:  2017        PMID: 28844013     DOI: 10.1016/j.drugalcdep.2017.06.033

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  5 in total

1.  Prescription Opioid Misuse Motives in US Older Adults.

Authors:  Ty S Schepis; Linda Wastila; Beth Ammerman; Vita V McCabe; Sean Esteban McCabe
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

2.  Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.

Authors:  Amanda B Namchuk; Irwin Lucki; Caroline A Browne
Journal:  Adv Drug Alcohol Res       Date:  2022-02-21

3.  Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats.

Authors:  Norsyifa Harun; Illa Syafiqah Johari; Sharif Mahsufi Mansor; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2019-12-12       Impact factor: 4.530

4.  Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report.

Authors:  Burak Kulaksızoğlu; Hüseyin Kara; Berkan Bodur; Murat Kuloğlu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-09       Impact factor: 2.570

Review 5.  Emerging Evidence for Cannabis' Role in Opioid Use Disorder.

Authors:  Beth Wiese; Adrianne R Wilson-Poe
Journal:  Cannabis Cannabinoid Res       Date:  2018-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.